FBIOP (Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock)
Insider Trading Activity
Every open-market purchase and sale reported by FBIOP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | David Jin | Chief Financial Officer | A | — | — |
| 2026-03-20 | LINDSAY A MD ROSENWALD | PRESIDENT, CEO & CHAIRMAN | A | — | — |
| 2026-03-20 | MICHAEL S WEISS | Executive Vice Chairman | A | — | — |
| 2026-01-05 | J JAY LOBELL | Director | A | — | — |
| 2026-01-05 | Kevin Lorenz | Director | A | — | — |
| 2026-01-05 | Malcolm Hoenlein | Director | A | — | — |
| 2026-01-05 | Dov Klein | Director | A | — | — |
| 2026-01-05 | Jimmie Harvey | Director | A | — | — |
| 2025-10-02 | David Jin | Chief Financial Officer | A | — | — |
| 2025-04-01 | David Jin | Chief Financial Officer | A | — | — |
| 2025-01-03 | MICHAEL S WEISS | Executive Vice Chairman | A | — | — |
| 2025-01-03 | J JAY LOBELL | Director | A | — | — |
| 2025-01-03 | Jimmie Harvey | Director | A | — | — |
| 2025-01-03 | LINDSAY A MD ROSENWALD | PRESIDENT, CEO & CHAIRMAN | A | — | — |
| 2025-01-03 | Kevin Lorenz | Director | A | — | — |
| 2025-01-03 | Dov Klein | Director | A | — | — |
| 2025-01-03 | Lucy Lu | Director | A | — | — |
| 2025-01-03 | Malcolm Hoenlein | Director | A | — | — |
| 2024-12-23 | David Jin | Chief Financial Officer | A | — | — |
| 2024-10-01 | David Jin | Chief Financial Officer | A | — | — |
| 2024-09-25 | LINDSAY A MD ROSENWALD | PRESIDENT, CEO & CHAIRMAN | Buy | — | — |
| 2024-07-15 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2024-07-12 | David Jin | Chief Financial Officer | Buy | — | — |
| 2024-07-11 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2024-07-10 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2024-07-01 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2024-05-20 | Dov Klein | Director | Sell | — | — |
| 2024-05-20 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2024-04-02 | David Jin | Chief Financial Officer | A | — | — |
| 2024-01-09 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2024-01-03 | Lucy Lu | Director | A | — | — |
| 2024-01-03 | Malcolm Hoenlein | Director | A | — | — |
| 2024-01-03 | Dov Klein | Director | A | — | — |
| 2024-01-03 | Jimmie Harvey | Director | A | — | — |
| 2024-01-03 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | A | — | — |
| 2024-01-03 | J JAY LOBELL | Director | A | — | — |
| 2024-01-03 | Kevin Lorenz | Director | A | — | — |
| 2024-01-03 | MICHAEL S WEISS | See Remarks | A | — | — |
| 2024-01-03 | Eric K Rowinsky | Director | A | — | — |
| 2023-12-22 | David Jin | Chief Financial Officer | A | — | — |
| 2023-11-16 | MICHAEL S WEISS | See Remarks | Buy | — | — |
| 2023-11-16 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2023-09-27 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2023-08-21 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2023-02-14 | MICHAEL S WEISS | See Remarks | Buy | — | — |
| 2023-02-14 | Eric K Rowinsky | Director | Buy | — | — |
| 2023-02-14 | LINDSAY A MD ROSENWALD | President, CEO & Chairman | Buy | — | — |
| 2023-02-14 | Lucy Lu | Director | Buy | — | — |
| 2023-02-14 | J JAY LOBELL | Director | Buy | — | — |
| 2023-02-14 | David Jin | Chief Financial Officer | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | PRESIDENT, CEO & CHAIRMAN | 4,586,841 | — |
| — | Executive Vice Chairman | 2,276,562 | — |
| — | Chief Financial Officer | 1,251,571 | — |
| — | SVP, BIOLOGICS OPERATIONS | 655,170 | — |
| — | Director | 192,397 | — |
| — | Chief Financial Officer | 163,877 | — |
| — | Director | 146,704 | — |
| — | Director | 131,905 | — |
| — | Director | 115,747 | — |
| — | Director | 101,675 | — |
| — | Director | 68,797 | — |
| — | Director | 61,273 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FBIOP quote page; the site-wide leaderboard is on the insider transactions hub.